NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.10M | 1.07M | 983.00K | 242.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.10M | 1.07M | 983.00K | 242.00K | -- |
| Cost of Revenue | 675.00K | 631.00K | 408.00K | 97.00K | -- |
| Gross Profit | 426.00K | 437.00K | 575.00K | 145.00K | -- |
| SG&A Expenses | 4.75M | 3.81M | 4.57M | 2.81M | 2.74M |
| Depreciation & Amortization | 66.00K | 63.00K | 42.00K | 26.00K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.60M | 5.82M | 5.58M | 4.36M | 3.73M |
| Operating Income | -6.50M | -4.75M | -4.59M | -4.12M | -3.73M |
| Income Before Tax | -16.52M | -1.43M | 360.00K | -5.89M | -17.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.52M | -1.43M | 360.00K | -5.89M | -17.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.52M | -1.43M | 360.00K | -5.89M | -17.58M |
| EBIT | -6.50M | -4.75M | -4.59M | -4.12M | -3.73M |
| EBITDA | -6.43M | -4.69M | -4.55M | -4.11M | -3.73M |
| EPS Basic | -0.44 | -0.04 | 0.01 | -0.26 | -0.98 |
| Normalized Basic EPS | -0.27 | -0.03 | -0.08 | -0.13 | -0.42 |
| EPS Diluted | -0.44 | -0.04 | 0.01 | -0.26 | -0.98 |
| Normalized Diluted EPS | -0.27 | -0.03 | -0.08 | -0.13 | -0.42 |
| Average Basic Shares Outstanding | 37.65M | 32.33M | 28.96M | 22.23M | 17.93M |
| Average Diluted Shares Outstanding | 37.65M | 32.33M | 28.96M | 22.23M | 17.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |